RELMADA THERAPEUTICS, INC. — Director's Dealing 2021

Dec 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-12-17

Reporting Person: Shenouda Maged (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-17	Stock Option (right to buy)	$19.03	A	227518	Acquired	2031-12-17	Common Stock (227518)	Direct

Footnotes

F1: The option vests in 16 equal quarterly installments commencing on March 17, 2022.